SRPT Sarepta Therapeutics
- 131.380
- -1.360-1.02%
- 130.000
- -1.380-1.05%
Sarepta Therapeutics News
Sarepta Therapeutics Is Maintained at Buy by Mizuho
Sarepta Therapeutics Is Maintained at Buy by Mizuho
Mizuho Maintains Buy on Sarepta Therapeutics, Raises Price Target to $179
Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $145 to $179.
Buy Rating for Sarepta Therapeutics' Elevidys Supported by Positive Regulatory Signals
Sarepta Upgraded at Oppenheimer on Potential Elevidys Label Expansion
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target Is $180
Sarepta Therapeutics (SRPT) has an average rating of outperform and price targets ranging from $128 to $224, according to analysts polled by Capital IQ. Price: 134.00, Change: +2.30, Percent Change: +
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Boy Given Pfizer Experimental Duchenne Muscular Dystrophy Therapy Dies
Sarepta Therapeutics Shares Move Higher; Traders Circulate STAT News Report 'Young Boy Dies in Trial for Pfizer Duchenne Gene Therapy.' BZ NOTE: Co Makes Competing DMD Drug
Sarepta Therapeutics Shares Move Higher; Traders Circulate STAT News Report 'Young Boy Dies in Trial for Pfizer Duchenne Gene Therapy.' BZ NOTE: Co Makes Competing DMD Drug
Sarepta Therapeutics(SRPT.US) Officer Sells US$508.9K in Common Stock
$Sarepta Therapeutics(SRPT.US)$ Officer Murray Dallan sold 3,635 shares of common stock on May 2, 2024 at an average price of $140 for a total value of $508.9K.Source: Announcement(one of the forms) W
JP Morgan Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $175
JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics with a Overweight and lowers the price target from $177 to $175.
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says
Sarepta Therapeutics' (SRPT) regulatory review of its Elevidys therapy for Duchenne muscular dystrophy is advancing faster than anticipated, Morgan Stanley said in a report emailed Thursday. "Overall,
Sarepta Elevidys Accelerated Approval Criticized by ICER Exec
Sarepta Therapeutics Price Target Maintained With a $128.00/Share by Cantor Fitzgerald
Sarepta Therapeutics Price Target Maintained With a $128.00/Share by Cantor Fitzgerald
Cantor Fitzgerald, Inc.: Reiterates the Sarepta Therapeutics (SRPT.US) rating and adjusted from neutral to neutral, with a target price of $128.00.
Cantor Fitzgerald, Inc.: Reiterates the Sarepta Therapeutics (SRPT.US) rating and adjusted from neutral to neutral, with a target price of $128.00.
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating
Sarepta Therapeutics (SRPT) has an average outperform rating and a price target range of $128 to $224, according to analysts polled by Capital IQ. Price: 134.86, Change: +3.96, Percent Change: +3.03
Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Needham Reiterates Buy on Sarepta Therapeutics, Maintains $166 Price Target
Needham analyst Gil Blum reiterates Sarepta Therapeutics with a Buy and maintains $166 price target.
Sarepta Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 19.73% Needham → $166 Reiterates Buy → Buy 03/01/2024 20.45% UBS $164 → $167 Maintains Buy 02/2
Buy Rating on Sarepta Therapeutics Amid Anticipated Label Expansion for Elevidys
Analysis
Price Target
No Data
